Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference
December 05 2022 - 7:00AM
Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of
Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) today announced
that the company will participate in the investor-focused Cantor
Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and
Medtech/Diagnostic Conference, which is taking place in Miami on
December 8.
September Riharb, Senior Vice President of Marketing for Jeune,
will participate in an aesthetic dermatology panel on December 8 at
11:00 am ET, Distraction or Destruction: What’s New/Next in the
Industry. The Jeune and Krystal management team will also
attend investor meetings on December 8.
About Jeune Aesthetics, Inc.
Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal
Biotech, Inc., is a biotechnology company leveraging a clinically
validated gene-delivery platform to fundamentally address – and
reverse – the biology of aging skin. For more information, please
visit http://www.jeuneinc.com.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a biotechnology
company focused on developing and commercializing genetic medicines
for patients with rare diseases. The Company’s wide-ranging
pipeline is based on its proprietary redosable HSV vector.
Headquartered in Pittsburgh, Pennsylvania, the Company is led
by an experienced management team, is fully-integrated and has core
capabilities in viral vector design, vector optimization, gene
therapy manufacturing and commercialization. For more information,
please visit http://www.krystalbio.com, and follow
@KrystalBiotech on LinkedIn and Twitter.
CONTACT:
Investors and Media:Meg DodgeKrystal
Biotechmdodge@krystalbio.com
Source: Krystal Biotech, Inc.
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Oct 2023 to Oct 2024